The question is whether the lowered sales projections from the sell-side analysts have assumed a sharp reduction in ASP or have assumed a price increase to offset some or all of the effect from the lower average dose. The second scenario is of course more bearish insofar as it means the reduced sales projections are based largely or entirely on reduced volume.